UK Share Watch

Leaders of Biotherapeutics Trailblazer PureTech Health Poised for Insightful Engagement at Esteemed Global Healthcare Conference

Clinical-stage biotherapeutics company PureTech Health is set to make a promising impact at the Jefferies Global Healthcare Conference. The company’s Chief Executive Officer, Bharatt Chowrira, PhD, JD, and Co-founder and President, Eric Elenko, PhD, are slated to take part in an engaging fireside chat. The discussion, happening on June 5, 2025, is anticipated to offer insightful information about PureTech’s groundbreaking work in biotherapeutics.

PureTech Health is devoted to developing novel classes of medicines designed to combat devastating diseases, thus altering the lives of patients for the better. Over the years, the company has built an extensive and diverse portfolio, thanks to its seasoned research and development team, combined with a broad network of scientific, clinical, and industry leaders. The success of their dedicated team has resulted in the development of 29 therapeutics and therapeutic candidates, with three of those approved by the U.S. Food and Drug Administration.

22-05-2025

Pharmaceutical Titans Novo Nordisk and Septerna Partner Up to Conquer Obesity and Boost Cardiometabolic Health

In a bold move promising to revolutionise healthcare, Novo Nordisk and Septerna have forged an extraordinary alliance, aimed at exploiting cutting-edge science to combat obesity and other cardiometabolic illnesses. This collaboration promises to push the frontiers of medicine, specifically targeting G protein-coupled receptor (GPCR) drug discovery, with an aim to develop multiple oral small molecule therapies.\Notably, the partnership is poised to capitalise on the shared strengths of both companies. Novo Nordisk, with its rich history in obesity and diabetes innovation, is a giant in the scientific realm, while Septerna’s capabilities in GPCR drug discovery presents significant potential.

14-05-2025

A Revolutionary Leap in Ophthalmology as FDA Fast Tracks OKYO Pharma's Innovative Urcosimod for Neuropathic Corneal Pain

OKYO Pharma's ground-breaking drug, Urcosimod, aimed at tackling neuropathic corneal pain (NCP), has received Fast Track status from the U.S. Food and Drug Administration.

01-05-2025